Artículos de revistas sobre el tema "IRINOTECAN CANCER TREATMENT"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte los 50 mejores artículos de revistas para su investigación sobre el tema "IRINOTECAN CANCER TREATMENT".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.
Aoki, Masahiko, Hirokazu Shoji, Hiroshi Imazeki, Takahiro Miyamoto, Hidekazu Hirano, Yoshitaka Honma, Satoru Iwasa et al. "The hyperprogressive disease during nivolumab treatment or irinotecan treatment in patients with advanced gastric cancer." Journal of Clinical Oncology 37, n.º 4_suppl (1 de febrero de 2019): 124. http://dx.doi.org/10.1200/jco.2019.37.4_suppl.124.
Texto completoFalcone, Alfredo, Antonello Di Paolo, Gianluca Masi, Giacomo Allegrini, Romano Danesi, Monica Lencioni, Elisabetta Pfanner, Silvia Comis, Mario Del Tacca y Pierfranco Conte. "Sequence Effect of Irinotecan and Fluorouracil Treatment on Pharmacokinetics and Toxicity in Chemotherapy-Naive Metastatic Colorectal Cancer Patients". Journal of Clinical Oncology 19, n.º 15 (1 de agosto de 2001): 3456–62. http://dx.doi.org/10.1200/jco.2001.19.15.3456.
Texto completoVanhoefer, Udo, Andreas Harstrick, Wolf Achterrath, Shousong Cao, Siegfried Seeber y Youcef M. Rustum. "Irinotecan in the Treatment of Colorectal Cancer: Clinical Overview". Journal of Clinical Oncology 19, n.º 5 (1 de marzo de 2001): 1501–18. http://dx.doi.org/10.1200/jco.2001.19.5.1501.
Texto completoBailly, Christian. "Irinotecan: 25 years of cancer treatment". Pharmacological Research 148 (octubre de 2019): 104398. http://dx.doi.org/10.1016/j.phrs.2019.104398.
Texto completoKockaya, Guvenc, Mine Polat, Albert Wertheimer, Ahmet Ozet, Simten Malhan, İsmail Mert Vural, Akif Akbulat, Guven Artıran, Hakkı Gursoz y Saim Kerman. "Treatment cost of metastatic colon cancer in Turkey". Farmeconomia. Health economics and therapeutic pathways 14, n.º 1 (30 de enero de 2013): 19–25. http://dx.doi.org/10.7175/fe.v14i1.472.
Texto completoRadajewska, Anna, Helena Moreira, Dorota Bęben, Oliwia Siwiela, Anna Szyjka, Katarzyna Gębczak, Paulina Nowak et al. "Combination of Irinotecan and Melatonin with the Natural Compounds Wogonin and Celastrol for Colon Cancer Treatment". International Journal of Molecular Sciences 24, n.º 11 (31 de mayo de 2023): 9544. http://dx.doi.org/10.3390/ijms24119544.
Texto completoAoki, Masahiko, Hirokazu Shoji, Kengo Nagashima, Hiroshi Imazeki, Takahiro Miyamoto, Hidekazu Hirano, Yoshitaka Honma et al. "Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer". ESMO Open 4, n.º 3 (mayo de 2019): e000488. http://dx.doi.org/10.1136/esmoopen-2019-000488.
Texto completoKciuk, Mateusz, Beata Marciniak y Renata Kontek. "Irinotecan—Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview". International Journal of Molecular Sciences 21, n.º 14 (12 de julio de 2020): 4919. http://dx.doi.org/10.3390/ijms21144919.
Texto completoSagawa, Tamotsu, Hironaga Satake, Koshi Fujikawa, Yukimasa Hatachi, Hisateru Yasui, Masahito Kotaka, Takeshi Kato y Akihito Tsuji. "Phase Ib study of ramucirumab and irinotecan for metastatic gastric cancer previously treated with fluoropyrimidine with/without platina and taxane." Journal of Clinical Oncology 36, n.º 4_suppl (1 de febrero de 2018): 155. http://dx.doi.org/10.1200/jco.2018.36.4_suppl.155.
Texto completoShun, Yu-Ting, Hsien-Yung Lai, Yi-Ting Chuang y Hsuen-Fu Lin. "Successful Treatment of Irinotecan-Induced Muscle Twitching: A Case Report". Clinical Medicine Insights: Case Reports 16 (enero de 2023): 117954762211503. http://dx.doi.org/10.1177/11795476221150354.
Texto completoHulshof, Emma C., Mirjam de With, Femke M. de Man, Geert-Jan Creemers, Birgit ALM Deiman, Jesse J. Swen, Saskia Houterman et al. "Safety and pharmacokinetic analysis of UGT1A1 genotype-guided dosing of irinotecan." Journal of Clinical Oncology 39, n.º 15_suppl (20 de mayo de 2021): 3574. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.3574.
Texto completoJahan, Zeenat, Fahad A. Benthani, Nicola Currey, Hannah W. Parker, Jane E. Dahlstrom, C. Elizabeth Caldon y Maija R. J. Kohonen-Corish. "MCC Gene Silencing Is a CpG Island Methylator Phenotype-Associated Factor That Predisposes Colon Cancer Cells to Irinotecan and Olaparib". Cancers 14, n.º 12 (9 de junio de 2022): 2859. http://dx.doi.org/10.3390/cancers14122859.
Texto completoBugat, R. "Irinotecan in the treatment of gastric cancer". Annals of Oncology 14 (junio de 2003): ii37—ii40. http://dx.doi.org/10.1093/annonc/mdg727.
Texto completoWilke, H., O. Bouché, P. Rougier y C. H. Köhne. "Irinotecan for the treatment of gastric cancer". European Journal of Cancer Supplements 2, n.º 7 (junio de 2004): 48–51. http://dx.doi.org/10.1016/j.ejcsup.2004.04.015.
Texto completoFuchs, Charles, Edith P. Mitchell y Paulo M. Hoff. "Irinotecan in the treatment of colorectal cancer". Cancer Treatment Reviews 32, n.º 7 (noviembre de 2006): 491–503. http://dx.doi.org/10.1016/j.ctrv.2006.07.001.
Texto completoSobrero, Alberto F., Joan Maurel, Louis Fehrenbacher, Werner Scheithauer, Yousif A. Abubakr, Manfred P. Lutz, M. Eugenia Vega-Villegas et al. "EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer". Journal of Clinical Oncology 26, n.º 14 (10 de mayo de 2008): 2311–19. http://dx.doi.org/10.1200/jco.2007.13.1193.
Texto completoWang, Wenjie, Monica Rodriguez-Silva, Arlet M. Acanda de la Rocha, Aizik L. Wolf, Yanhao Lai, Yuan Liu, William C. Reinhold, Yves Pommier, Jeremy W. Chambers y Yuk-Ching Tse-Dinh. "Tyrosyl-DNA Phosphodiesterase 1 and Topoisomerase I Activities as Predictive Indicators for Glioblastoma Susceptibility to Genotoxic Agents". Cancers 11, n.º 10 (23 de septiembre de 2019): 1416. http://dx.doi.org/10.3390/cancers11101416.
Texto completoGiuliani, F. y G. Colucci. "Cetuximab in Colon Cancer". International Journal of Biological Markers 22, n.º 1_suppl4 (enero de 2007): 62–70. http://dx.doi.org/10.1177/17246008070221s408.
Texto completoHironaka, Shuichi, Shinya Ueda, Hirofumi Yasui, Tomohiro Nishina, Masahiro Tsuda, Takehiko Tsumura, Naotoshi Sugimoto et al. "Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial". Journal of Clinical Oncology 31, n.º 35 (10 de diciembre de 2013): 4438–44. http://dx.doi.org/10.1200/jco.2012.48.5805.
Texto completoStrock, Christopher J., Jong-In Park, D. Marc Rosen, Bruce Ruggeri, Samuel R. Denmeade, Douglas W. Ball y Barry D. Nelkin. "Activity of Irinotecan and the Tyrosine Kinase Inhibitor CEP-751 in Medullary Thyroid Cancer". Journal of Clinical Endocrinology & Metabolism 91, n.º 1 (1 de enero de 2006): 79–84. http://dx.doi.org/10.1210/jc.2005-1882.
Texto completoO'Reilly, Eileen Mary, Andy Surinach, Allison Dillon, Paul Cockrum y Kenneth H. Yu. "Impact of prior irinotecan exposure on outcomes of metastatic pancreatic cancer (mPC) patients." Journal of Clinical Oncology 38, n.º 4_suppl (1 de febrero de 2020): 667. http://dx.doi.org/10.1200/jco.2020.38.4_suppl.667.
Texto completoCunningham, Julia Marie, Petra Prins, Brian Conkright, Simina Boca, Shruti Rao, Andrew Gabrielson, Andrew Oseran et al. "Molecular profiling of TOPO1: A way to evaluate irinotecan treatment in colorectal cancer?" Journal of Clinical Oncology 34, n.º 4_suppl (1 de febrero de 2016): 546. http://dx.doi.org/10.1200/jco.2016.34.4_suppl.546.
Texto completoAmonkar, Mayur, David Gomez-Ulloa, Smita Kothari, Winson Y. Cheung, Ian Chau, John Raymond Zalcberg, Nuria Lara y Alfredo Falcone. "Real-world treatment patterns and clinical outcomes in patients receiving second-line (2L) treatment for advanced or metastatic gastric cancer (GC)." Journal of Clinical Oncology 37, n.º 4_suppl (1 de febrero de 2019): 102. http://dx.doi.org/10.1200/jco.2019.37.4_suppl.102.
Texto completoMir, Tanveer Ahmad, Ahmed S. Yassin, Eric Joseph Denha, Raad Al Shaikhli, Ali Rahim, Sabah Ambreen y Prateek Lohia. "Irinotecan inducing sinus pause bradycardia in a patient with small round cell cancer". BMJ Case Reports 13, n.º 5 (mayo de 2020): e232053. http://dx.doi.org/10.1136/bcr-2019-232053.
Texto completoKim, Seong-Ryong, Hyun Jung Lee y Dalyong Kim. "Consistent Response on Challenge and Rechallenge of Liposomal Irinotecan in a Patient with Metastatic Pancreatic Adenocarcinoma Previously Treated with Gemcitabine plus Nab-Paclitaxel: A Case Report". Case Reports in Oncology 14, n.º 3 (30 de diciembre de 2021): 1882–88. http://dx.doi.org/10.1159/000521315.
Texto completoJang, Hyun Joo, Eun Mi Hong, Juah Jang, Jung Eun Choi, Se Woo Park, Hyun Woo Byun, Dong Hee Koh, Min Ho Choi, Sea Hyub Kae y Jin Lee. "Synergistic Effects of Simvastatin and Irinotecan against Colon Cancer Cells with or without Irinotecan Resistance". Gastroenterology Research and Practice 2016 (2016): 1–9. http://dx.doi.org/10.1155/2016/7891374.
Texto completoGonzalez-Baron, M., M. Blanco, J. Feliu, C. Gómez, E. Casado, J. Castro, C. Belda-Iniesta, M. Garrido, C. Aguayo y M. A. Campos. "Cetuximab and irinotecan in patients with colorectal cancer refractory to oxaliplatin and irinotecan". Journal of Clinical Oncology 25, n.º 18_suppl (20 de junio de 2007): 14600. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.14600.
Texto completoLim, Sung Hee, Jae-Joon Kim, Hyeon-Su Im, Hye Sook Han, In-Ho Kim, Dong-Hoe Koo, Jang Ho Cho et al. "Comparison of efficacy between immune checkpoint inhibitors and irinotecan-based chemotherapy as third-line treatment for patients with advanced gastric cancer: A Korean real-world multicenter study (KCSG ST22-06)." Journal of Clinical Oncology 41, n.º 16_suppl (1 de junio de 2023): e16047-e16047. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e16047.
Texto completoGuo, Weijian, Xiaowei Zhang, Yusheng Wang, Wen Zhang, Xin Liu, Wei Shen, Yifu He et al. "FOLFIRI versus irinotecan monodrug as second-line treatment in metastatic colorectal cancer patients: An open, multicenter, prospective, randomized controlled phase III clinical study." Journal of Clinical Oncology 38, n.º 15_suppl (20 de mayo de 2020): 4038. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.4038.
Texto completoYu, Qianqian, Zhihuan Li, Xiaoqi Nie, Lu Wang, Chen Gong, Bo Liu, Xin Liao et al. "Predictive Value of UGT1A1 Polymorphisms in Irinotecan-Induced Toxicity and Therapeutic Efficacy in Colorectal Cancer Patients". Journal of Cancer Treatment and Diagnosis 4, n.º 2 (1 de septiembre de 2020): 39–46. http://dx.doi.org/10.29245/2578-2967/2020/2.1182.
Texto completoPaulík, Adam, Jiří Grim y Stanislav Filip. "Predictors of Irinotecan Toxicity and Efficacy in Treatment of Metastatic Colorectal Cancer". Acta Medica (Hradec Kralove, Czech Republic) 55, n.º 4 (2012): 153–59. http://dx.doi.org/10.14712/18059694.2015.39.
Texto completoJanjigian, Yelena Yuriy, Laura H. Tang, Stephen Shibata, David Paul Kelsen, Michal Segal, Catherine Cheng, Gary K. Schwartz, L. Austin Doyle y Manish A. Shah. "A multicenter random assignment phase II study of irinotecan and flavopiridol versus irinotecan alone for patients with p53 wild-type gastric adenocarcinoma (NCI 8060)." Journal of Clinical Oncology 30, n.º 15_suppl (20 de mayo de 2012): e14586-e14586. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e14586.
Texto completoLal, Rohit, James Dickson, David Cunningham, Ian Chau, Andrew R. Norman, Paul J. Ross, Clare Topham, Gary Middleton, Mark Hill y Jacqui Oates. "A Randomized Trial Comparing Defined-Duration With Continuous Irinotecan Until Disease Progression in Fluoropyrimidine and Thymidylate Synthase Inhibitor—Resistant Advanced Colorectal Cancer". Journal of Clinical Oncology 22, n.º 15 (1 de agosto de 2004): 3023–31. http://dx.doi.org/10.1200/jco.2004.01.005.
Texto completoAlmasmoum, Hussain. "Characterization of mucin 2 expression in colorectal cancer with and without chemotherapies, in vivo and in vitro study". Journal of Umm Al-Qura University for Medical Sciences 7, n.º 1 (1 de junio de 2021): 18–22. http://dx.doi.org/10.54940/ms28179947.
Texto completoGatzemeier, U. "Options for Treatment of Lung Cancer with Irinotecan". Oncology Research and Treatment 23, n.º 4 (2000): 34–36. http://dx.doi.org/10.1159/000055055.
Texto completoDouillard, J.-Y. "Irinotecan: a new treatment in metastatic colorectal cancer". Journal of Oncology Pharmacy Practice 6, n.º 3 (1 de marzo de 2000): 3–9. http://dx.doi.org/10.1191/107815500117842.
Texto completoTakano, Masashi y Toru Sugiyama. "UGT1A1 polymorphisms in cancer: impact on irinotecan treatment". Pharmacogenomics and Personalized Medicine Volume10 (febrero de 2017): 61–68. http://dx.doi.org/10.2147/pgpm.s108656.
Texto completoDouillard, Jean-Yves. "Irinotecan: a new treatment in metastatic colorectal cancer". Journal of Oncology Pharmacy Practice 6, n.º 3_suppl (septiembre de 2000): S3—S9. http://dx.doi.org/10.1177/107815520000600i301.
Texto completoHaller, Daniel G., Mace L. Rothenberg, Alfred O. Wong, Piotr M. Koralewski, Wilson H. Miller, Gyorgy Bodoky, Nassir Habboubi, Carlos Garay y Luis O. Olivatto. "Oxaliplatin Plus Irinotecan Compared With Irinotecan Alone as Second-Line Treatment After Single-Agent Fluoropyrimidine Therapy for Metastatic Colorectal Carcinoma". Journal of Clinical Oncology 26, n.º 28 (1 de octubre de 2008): 4544–50. http://dx.doi.org/10.1200/jco.2008.17.1249.
Texto completoKawakami, Takeshi, Nozomu Machida, Masahiro Kawahira, Sadayuki Kawai, Yosuke Kito, Yukio Yoshida, Satoshi Hamauchi et al. "Efficacy and safety of irinotecan monotherapy as third line treatment for advanced gastric cancer." Journal of Clinical Oncology 34, n.º 4_suppl (1 de febrero de 2016): 113. http://dx.doi.org/10.1200/jco.2016.34.4_suppl.113.
Texto completoHutchcraft, Megan L., Nan Lin, Shulin Zhang, Catherine Sears, Kyle Zacholski, Elizabeth A. Belcher, Eric B. Durbin et al. "Real-World Evaluation of Universal Germline Screening for Cancer Treatment-Relevant Pharmacogenes". Cancers 13, n.º 18 (8 de septiembre de 2021): 4524. http://dx.doi.org/10.3390/cancers13184524.
Texto completoIshii, Takahiro, Akihito Kawazoe, Akinori Sasaki, Saori Mishima, Sawada Kentaro, Yoshiaki Nakamura, Daisuke Kotani et al. "Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer". Therapeutic Advances in Medical Oncology 12 (enero de 2020): 175883592094237. http://dx.doi.org/10.1177/1758835920942377.
Texto completoScheithauer, Werner, Gabriela V. Kornek, Markus Raderer, Herbert Ulrich-Pur, Wolfgang Fiebiger, Claudia Gedlicka, Birgit Schüll et al. "Randomized Multicenter Phase II Trial of Oxaliplatin Plus Irinotecan Versus Raltitrexed as First-Line Treatment in Advanced Colorectal Cancer". Journal of Clinical Oncology 20, n.º 1 (1 de enero de 2002): 165–72. http://dx.doi.org/10.1200/jco.2002.20.1.165.
Texto completoYu, Kenneth H., Andrew Eugene Hendifar, Olatunji B. Alese, Amber Draper, Maen Abdelrahim, Ethan Burns, Gazala Naaz Khan et al. "A multicenter chart review study of patients with metastatic pancreatic ductal adenocarcinoma receiving liposomal irinotecan after gemcitabine-based therapy." Journal of Clinical Oncology 38, n.º 15_suppl (20 de mayo de 2020): e16733-e16733. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e16733.
Texto completoSmith, Caleb J., Tanios S. Bekaii-Saab, Kathryn Cook, Rachel Eiring, Thorvardur Ragnar Halfdanarson, Mina Samir Erian Hanna, Zhaohui Jin et al. "Nanoliposomal irinotecan-based chemotherapy after regular irinotecan-based chemotherapy in patients with pancreas cancer." Journal of Clinical Oncology 39, n.º 3_suppl (20 de enero de 2021): 402. http://dx.doi.org/10.1200/jco.2021.39.3_suppl.402.
Texto completoKehrer, Diederik F. S., Ron H. J. Mathijssen, Jaap Verweij, Peter de Bruijn y Alex Sparreboom. "Modulation of Irinotecan Metabolism by Ketoconazole". Journal of Clinical Oncology 20, n.º 14 (15 de julio de 2002): 3122–29. http://dx.doi.org/10.1200/jco.2002.08.177.
Texto completoEbrahimpour, Mahnaz, Mahshid Mohammadian, Bagher Pourheydar, Zhino Moradi y Zhaleh Behrouzkia. "Effects of Radiotherapy in Combination With Irinotecan and 17-AAG on Bcl-2 and Caspase 3 Gene Expression in Colorectal Cancer Cells". Journal of Lasers in Medical Sciences 13, n.º 1 (28 de febrero de 2022): e9-e9. http://dx.doi.org/10.34172/jlms.2022.09.
Texto completoKim, George P., Daniel J. Sargent, Michelle R. Mahoney, Kendrith M. Rowland, Philip A. Philip, Edith Mitchell, Abraham P. Mathews et al. "Phase III Noninferiority Trial Comparing Irinotecan With Oxaliplatin, Fluorouracil, and Leucovorin in Patients With Advanced Colorectal Carcinoma Previously Treated With Fluorouracil: N9841". Journal of Clinical Oncology 27, n.º 17 (10 de junio de 2009): 2848–54. http://dx.doi.org/10.1200/jco.2008.20.4552.
Texto completoCockrum, Paul, Andy Surinach, Stella Arndorfer, Jim M. Koeller y George P. Kim. "National Comprehensive Cancer Network (NCCN) category I/FDA-approved metastatic pancreatic adenocarcinoma (mPDAC) treatments in commercially insured patients: An analysis of inpatient (IP) and emergency room (ER) admissions." Journal of Clinical Oncology 38, n.º 15_suppl (20 de mayo de 2020): e16739-e16739. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e16739.
Texto completoKipps, Emma, Kate Young y Naureen Starling. "Liposomal irinotecan in gemcitabine-refractory metastatic pancreatic cancer: efficacy, safety and place in therapy". Therapeutic Advances in Medical Oncology 9, n.º 3 (marzo de 2017): 159–70. http://dx.doi.org/10.1177/1758834016688816.
Texto completo